Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

2021 ◽  
Vol 8 (4) ◽  
pp. e254-e266
Author(s):  
Jeff P Sharman ◽  
Danielle M Brander ◽  
Anthony R Mato ◽  
Nilanjan Ghosh ◽  
Stephen J Schuster ◽  
...  
Keyword(s):  
High Risk ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Randomised Trial ◽  
Open Label ◽  
Phase 3

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

2015 ◽  
Vol 16 (13) ◽  
pp. 1370-1379 ◽  
Author(s):  
Marinus H J van Oers ◽  
Kazimierz Kuliczkowski ◽  
Lukáš Smolej ◽  
Mario Petrini ◽  
Fritz Offner ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Open Label ◽  
Phase 3

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

The Lancet ◽  
2010 ◽  
Vol 376 (9747) ◽  
pp. 1164-1174 ◽  
Author(s):  
M Hallek ◽  
K Fischer ◽  
G Fingerle-Rowson ◽  
AM Fink ◽  
R Busch ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document